Acción IVCP SWIFTMERGE ACQUISITION CORP.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Swiftmerge Acquisition Corp.

Acciones

IVCP

KYG638361033

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:30:01 02/05/2024 		Varia. Cinco días. Varia. 1 de enero.
10,77 USD -0,19 % Gráfico intradía de Swiftmerge Acquisition Corp. -0,28 % -0,92 %
01/04 Swiftmerge Acquisition Corp. informa de los resultados del año completo finalizado el 31 de diciembre de 2023 CI
2023 Swiftmerge Acquisition Corp. informa de los resultados del tercer trimestre y los nueve meses finalizados el 30 de septiembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Swiftmerge Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Swiftmerge Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Swiftmerge Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Swiftmerge Acquisition : Non-Reliance on Previously Issued Financial Statements or Related Audit Report or Completed Interim Report - Form 8-K
Swiftmerge Acquisition Signs Merger Deal to Take HDL Therapeutics Public
HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.
SWIFTMERGE ACQUISITION CORP. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
Swiftmerge Acquisition : Adjournment of Extraordinary General Meeting - Form 8-K
Swiftmerge Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment
HDL Therapeutics, Inc. signed a non-binding letter of intent to acquire Swiftmerge Acquisition Corp. in a reverse merger transaction.
SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
SWIFTMERGE ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Swiftmerge Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
Swiftmerge Acquisition Corp. Auditor Raises 'Going Concern' Doubt
Swiftmerge Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Swiftmerge Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción IVCP
  4. Noticias Swiftmerge Acquisition Corp.
  5. Otros idiomas